ProMIS Neurosciences Announces Private Placement Financing

Core Points - ProMIS Neurosciences, Inc. has announced a private investment in public equity (PIPE) financing, raising approximately $2.4 million through the issuance of warrants, with total gross proceeds expected to reach $9.2 million when including additional funds from existing warrant exercises [1][3] - The warrants have an exercise price of $1.25 per share, are immediately exercisable, and will expire five years from the date of issuance [2] - Proceeds from the PIPE financing will be utilized to advance the clinical development of PMN310, the company's lead therapeutic candidate, as well as for working capital and general corporate expenses [4] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies targeting toxic misfolded proteins associated with neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease [7] - The company employs a proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in various neurodegenerative conditions [7]